TG Therapeutics (TGTX) Earns “Buy” Rating from Raymond James Financial
TG Therapeutics (NASDAQ:TGTX)‘s stock had its “buy” rating reiterated by analysts at Raymond James Financial in a research note issued on Tuesday.
Several other equities research analysts also recently weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $33.00 price objective (up from $18.00) on shares of TG Therapeutics in a report on Tuesday, November 14th. ValuEngine downgraded TG Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, October 16th. SunTrust Banks reissued a “buy” rating and issued a $28.00 price objective on shares of TG Therapeutics in a report on Tuesday, October 3rd. B. Riley started coverage on TG Therapeutics in a report on Friday, December 1st. They issued a “buy” rating and a $21.50 price objective for the company. Finally, BidaskClub upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 24th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $25.50.
TG Therapeutics (NASDAQ TGTX) traded down $0.20 during mid-day trading on Tuesday, hitting $8.05. The stock had a trading volume of 1,162,776 shares, compared to its average volume of 1,542,507. TG Therapeutics has a 1-year low of $4.10 and a 1-year high of $15.35.
Institutional investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. raised its stake in shares of TG Therapeutics by 44.0% during the second quarter. JPMorgan Chase & Co. now owns 364,025 shares of the biopharmaceutical company’s stock worth $3,658,000 after purchasing an additional 111,155 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in shares of TG Therapeutics by 152.8% during the first quarter. Goldman Sachs Group Inc. now owns 43,020 shares of the biopharmaceutical company’s stock worth $501,000 after purchasing an additional 26,001 shares during the last quarter. Dupont Capital Management Corp purchased a new stake in shares of TG Therapeutics during the second quarter worth approximately $258,000. Ameriprise Financial Inc. raised its stake in shares of TG Therapeutics by 150.2% during the second quarter. Ameriprise Financial Inc. now owns 277,235 shares of the biopharmaceutical company’s stock worth $2,786,000 after purchasing an additional 166,434 shares during the last quarter. Finally, Franklin Resources Inc. raised its stake in shares of TG Therapeutics by 20.6% during the second quarter. Franklin Resources Inc. now owns 2,339,166 shares of the biopharmaceutical company’s stock worth $23,509,000 after purchasing an additional 398,916 shares during the last quarter. Institutional investors and hedge funds own 50.45% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This article was originally published by American Banking News and is owned by of American Banking News. If you are viewing this article on another domain, it was copied illegally and republished in violation of international trademark & copyright legislation. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/12/12/tg-therapeutics-tgtx-earns-buy-rating-from-raymond-james-financial.html.
About TG Therapeutics
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.